Hybio Pharmaceutical Co., Ltd. (SHE:300199)

China · Delayed Price · Currency is CNY

21.86

-0.45 (-2.02%)

Oct 30, 2026, 3:04 PM CST

Hybio Pharmaceutical Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Revenue	1,526	966.35	590.2	431.38	704.32	735.97
Revenue Growth	69.87%	63.73%	36.81%	-38.75%	-4.30%	1.97%
Gross Profit	935.54	539.12	308.73	170.97	509.49	464.1
Operating Income	481.94	168.34	-32.41	-371.41	-182.13	-270.27
Net Income	401.86	36.57	-173.65	-513.88	-370.55	30.81
Earnings Per Share	0.44	0.04	-0.20	-0.58	-0.42	0.03
EPS Growth	-	-	-	-	-	-

Revenue by Geography

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
China	367.93	265.02	319.17	625.06	689.03
Foreign	598.42	325.18	112.21	79.26	46.94
Total	966.35	590.2	431.38	704.32	735.97

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Cash & Investments	205.63	101.95	95.97	344.01	266.83	616.6
Total Debt	1,873	1,910	1,798	2,030	1,806	1,789
Net Cash (Debt)	-1,668	-1,808	-1,702	-1,686	-1,540	-1,173
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-1.83	-1.98	-1.96	-1.90	-1.74	-1.14

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Operating Cash Flow	341.56	233.9	164.71	-3.54	15.81	156.83
Capital Expenditures	-326.79	-234.35	-115.84	-81.76	-189.85	-199
Free Cash Flow	14.76	-0.45	48.87	-85.3	-174.04	-42.17
Free Cash Flow Growth	-88.55%	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Gross Margin	61.32%	55.79%	52.31%	39.63%	72.34%	63.06%
Operating Margin	31.59%	17.42%	-5.49%	-86.10%	-25.86%	-36.72%
Pretax Margin	28.70%	6.65%	-27.52%	-118.48%	-52.93%	4.58%
Profit Margin	26.34%	3.78%	-29.42%	-119.12%	-52.61%	4.19%
FCF Margin	0.97%	-0.05%	8.28%	-19.77%	-24.71%	-5.73%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct '26 Oct 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
PE Ratio	49.70	432.32	-	-	-	361.52
Forward PE	-	9.21	9.21	9.21	9.21	9.21
P/FCF Ratio	1307.88	-	232.96	-	-	-
PS Ratio	12.66	16.36	19.29	27.80	22.05	15.13